Eledon Pharmaceuticals Total Current Liabilities Over Time
ELDN Stock | USD 4.85 0.25 5.43% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Eledon Pharmaceuticals Performance and Eledon Pharmaceuticals Correlation. Eledon |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.73 | Return On Assets (0.33) | Return On Equity (0.25) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Liabilities Analysis
Compare Eledon Pharmaceuticals and related stocks such as Bolt Biotherapeutics, Keros Therapeutics, and Kezar Life Sciences Total Current Liabilities Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BOLT | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 8.7 M | 11.3 M | 21.3 M | 23.1 M | 20.5 M | 16.1 M |
KROS | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 4.5 M | 7.2 M | 11.8 M | 16.5 M | 24.4 M | 13.9 M |
KZR | 651 K | 651 K | 651 K | 651 K | 651 K | 651 K | 651 K | 1.5 M | 3.3 M | 6 M | 6.4 M | 8.2 M | 11 M | 17.7 M | 18.6 M |
REPL | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 5.2 M | 9.9 M | 11.9 M | 14.5 M | 20.8 M | 33.8 M | 40.4 M | 42.5 M |
NVCT | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 2.4 M | 6.2 M | 7 M | 4.3 M |
LYRA | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 5.2 M | 4.9 M | 18.2 M | 14.5 M | 19.6 M | 11.8 M |
KRON | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 2.7 M | 12.9 M | 13.6 M | 21.5 M | 24.7 M | 14.1 M |
GOSS | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 143 K | 1.3 M | 20.4 M | 36.9 M | 38.6 M | 39.9 M | 49.2 M | 51.6 M | 32.7 M |
APM | 269.8 K | 269.8 K | 269.8 K | 269.8 K | 269.8 K | 269.8 K | 269.8 K | 1.3 M | 12.2 M | 2.7 M | 3.9 M | 4.4 M | 12.5 M | 2.1 M | 2 M |
Eledon Pharmaceuticals and related stocks such as Bolt Biotherapeutics, Keros Therapeutics, and Kezar Life Sciences Total Current Liabilities description
Total Current Liabilities is an item on Eledon Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Eledon Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.My Equities
My Current Equities and Potential Positions
Eledon Pharmaceuticals | ELDN |
Classification | Pharmaceutical Products |
Location | California; U.S.A |
Exchange | NASDAQ Exchange |
USD 4.85
Check out Eledon Pharmaceuticals Performance and Eledon Pharmaceuticals Correlation. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Eledon Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.